Neuroinflammation is a hallmark feature of all major neurodegenerative diseases, including Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Lobar Degeneration (FTLD), and Huntington's Disease (HD). While each disease has distinct pathological features, the inflammatory response shares common cellular players—primarily microglia and astrocytes—and overlapping molecular pathways. This comparison page synthesizes current understanding of neuroinflammation across these five major neurodegenerative conditions.
Neuroinflammation in neurodegenerative diseases involves:
The key question remains whether neuroinflammation is a cause or consequence of neurodegeneration—likely it is both, creating a vicious cycle that accelerates disease progression[1].
| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTLD | Huntington's Disease |
|---|---|---|---|---|---|
| Primary Trigger | Aβ plaques, tau tangles | α-synuclein aggregates | TDP-43, SOD1, C9orf72 | Tau, TDP-43 | Mutant huntingtin (mHTT) |
| Key Microglial Receptors | TREM2, TLR4, CD33 | TLR2, TLR4, NLRP3 | TREM2, CCR2 | TREM2, TLR4 | TREM2, P2X7 |
| Pro-inflammatory Cytokines | IL-1β, IL-6, TNF-α | IL-1β, IL-6, TNF-α | IL-1β, IL-6, TNF-α | IL-1β, IL-6, TNF-α | IL-1β, IL-6, TNF-α |
| Complement Activation | C1q, C3, C4 | C1q, C3 | C1q, C3 | C1q, C3 | C1q, C3 |
| NLRP3 Inflammasome | Activated | Activated | Activated | Activated | Activated |
| Blood-Brain Barrier | Compromised | Compromised | Compromised | Variable | Compromised |
| Astrogliosis | Prominent | Prominent | Prominent | Prominent | Prominent |
| Temporal Onset | Pre-plaque, progressive | Pre-motor, progressive | Early, rapidly progressive | Variable | Pre-manifest, progressive |
| Regional Pattern | Limbic → cortical | Substantia nigra → cortex | Motor cortex → spinal cord | Frontotemporal | Striatum → cortex |
Neuroinflammation follows distinct temporal and spatial progression patterns across neurodegenerative diseases, reflecting the underlying pathology and regional vulnerability of each condition.
In AD, microglial activation can be detected before significant amyloid plaque deposition, suggesting inflammation may play an early pathogenic role[2]. PET imaging using TSPO (translocator protein) ligands reveals progressive inflammation in the entorhinal cortex, hippocampus, and inferior temporal gyrus that correlates with amyloid burden and cognitive decline[3]. The inflammatory response intensifies as tau pathology spreads from limbic regions to the neocortex, with microglia transitioning from a protective "disease-associated" phenotype to a more damaging state[4]. Longitudinal studies show that neuroinflammation peaks in moderate disease stages and remains elevated throughout progression.
In PD, neuroinflammation precedes motor symptoms by years—PET studies show microglial activation in the substantia nigra and striatum of patients with REM sleep behavior disorder (a prodromal PD marker)[5]. The progression follows a predictable pattern: substantia nigra → basal ganglia → cortical regions, mirroring the spread of alpha-synuclein pathology. Unlike AD, PD shows prominent activation in brainstem regions early, with later cortical involvement corresponding to cognitive decline and dementia[6].
ALS shows the most rapid progression of neuroinflammation, with microglial activation detected in the motor cortex and spinal cord at disease onset. The inflammatory response follows a "centrifugal" pattern—starting in motor regions and spreading to surrounding areas[7]. CSF biomarkers show dramatically elevated inflammatory markers (IL-6, TNF-α, MCP-1) at diagnosis, with levels remaining high throughout disease progression. Unlike other neurodegenerative diseases, ALS shows bidirectional inflammation-neurodegeneration: motor neuron death actively drives microglial activation, which in turn accelerates remaining neuron loss.
FTLD shows highly variable neuroinflammation patterns depending on the underlying proteinopathy. FTLD-tau (including PSP and CBD) shows inflammation that closely tracks tau burden, while FTLD-TDP shows inflammation that can exceed the detectable protein load[8]. The regional distribution matches the characteristic frontotemporal atrophy, with inflammation prominent in the frontal cortex, anterior temporal lobe, and anterior cingulate. Inflammation correlates with behavioral symptoms and disease aggressiveness.
Neuroinflammation in HD is detectable decades before clinical onset[9]. PET studies in premanifest gene carriers show elevated TSPO binding in the striatum and cortex, indicating early microglial activation. The inflammatory response intensifies as the disease progresses, with maximal activation in the caudate nucleus and putamen corresponding to the most severe neuronal loss. Longitudinal studies show that inflammatory markers (IL-6, CRP) predict disease progression rate and correlate with CAG repeat length.
In AD, neuroinflammation is driven primarily by amyloid-beta (Aβ) plaques and tau neurofibrillary tangles. Microglial activation occurs through:
The microglial phenotypic shift from protective (surveillance) to damaging state correlates with disease progression. TREM2 variants dramatically increase AD risk, highlighting the importance of microglial function.
In PD, neuroinflammation is triggered by:
Post-mortem studies show elevated microglia in substantia nigra, and PET imaging with TSPO ligands confirms chronic microglial activation in living patients[5:1].
ALS features neuroinflammation driven by:
Neuroinflammation in ALS spreads in a pattern matching disease progression—starting in motor cortex and spinal cord, affecting surrounding regions over time[7:1].
FTLD shows neuroinflammation associated with:
Microglial activation correlates with tau burden in FTLD-tau, while FTLD-TDP shows inflammation independent of protein load—suggesting different inflammatory mechanisms[14].
HD demonstrates neuroinflammation from:
Longitudinal studies show neuroinflammation precedes manifest HD in gene carriers, suggesting inflammation as an early disease marker[9:1].
| Target | Drug Class | Disease Context | Status |
|---|---|---|---|
| NLRP3 | Small molecule inhibitors | AD, PD, ALS | Preclinical |
| TREM2 | Agonistic antibodies | AD | Phase 2 |
| CD33 | Blocking antibodies | AD | Preclinical |
| TNF-α | Etanercept (peripheral) | PD | Failed trials |
| IL-1β | Canakinumab | AD | Phase 2/3 |
| CSF1R | Small molecule inhibitors | ALS, HD | Phase 1/2 |
| Trial ID | Agent | Target | Disease | Phase | Status |
|---|---|---|---|---|---|
| NCT02055027 | TWEAK抑制剂 | NLRP3/TAK1 | ALS | 2 | Completed |
| NCT01703091 | Etanercept | TNF-α | PD | 2 | Completed |
| NCT02555384 | TREM2激动剂 | TREM2 | AD | 1b | Completed |
| NCT02423122 | Sargramostim | GM-CSF | AD | 2 | Completed |
| NCT03943264 | Anifrolumab | IFN-α receptor | AD | 2 | Recruiting |
| NCT04577382 | Buntanetap | TNF-α, IL-1β, IL-6 | PD | 2a | Recruiting |
| NCT05663498 | Lomeguatrib + Temozolomide | MGMT, DNA repair | ALS | 1 | Recruiting |
| NCT04057834 | CNM-Au8 | NAD+ metabolism | ALS/PD | 2 | Active |
TREM2 Agonists (AD):
TNF-α Inhibition (PD):
NLRP3 Inhibitors:
Microglial Reprogramming: Using CSF1R antagonists to deplete disease-associated microglia and repopulate with healthy microglia[18]
TREM2-Targeting ASOs: Antisense oligonucleotides designed to modulate TREM2 expression levels
Complement Inhibition: C1q and C3 inhibitors to prevent aberrant synaptic pruning[19]
Tyrorosine Kinase Inhibitors: Bruton's TK inhibitors showing anti-inflammatory effects in microglia
CB2 Receptor Agonists: Targeting cannabinoid receptor 2 on microglia for anti-inflammatory effects without psychoactive effects
Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurology. 2015. ↩︎
Gerrits E, Broux B, Ghorbani ME, et al. Microglial alterations in Alzheimer's disease based on human brain studies. Acta Neuropathologica. 2024. ↩︎
Ikonomovic MD, Klunk WE. " Neuroinflammation and amyloid: emerging PET imaging biomarkers for Alzheimer disease". Radiology. 2022. ↩︎
Pradier L, McKinnon CS, Ramakrishnan C, et al. Divergent microglial responses to amyloid and tau pathology in mouse models of Alzheimer's disease. Nature Neuroscience. 2023. ↩︎
Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Annals of Neurology. 2005. ↩︎ ↩︎
Miron J, Picard C, Fragnaud L, et al. IL-1R1 signaling in tauopathy and alpha-synucleinopathies. Brain. 2023. ↩︎
Brites D, Vaz AR. 'Microglia centered pathogenesis in ALS: insights in search for treatments'. International Journal of Molecular Sciences. 2014. ↩︎ ↩︎
Wang R, Zhang C, Chen J, et al. Microglial activation patterns across neurodegenerative diseases. Trends in Neurosciences. 2024. ↩︎
Tai YF, Pavese N, Gerhard A, et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain. 2007. ↩︎ ↩︎
Wang Y, Cella M, Mallinson K, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. 2015. ↩︎
Bradshaw EM, Chibnik LB, Keenan BT, et al. 'CD33 Alzheimer''s disease locus: altered monocyte function and amyloid biology'. Nature Neuroscience. 2013. ↩︎
Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013. ↩︎
Fellner L, Irschick R, Schanda K, et al. Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia. 2013. ↩︎
Beach TG, McGeer EG. Lobular distribution of reactive microglia in Huntington's disease cortex. Neuroscience Letters. 1987. ↩︎
Schlepckow K, Monroe KM, Kleinberger G, et al. Enhancing protective microglial functions with TREM2 antibodies. Neuron. 2020. ↩︎
Brundin P, McArthur J. 'Etanercept in Parkinson''s disease: translating immunology into clinical impact'. Movement Disorders. 2015. ↩︎
Coll RC, Robertson AA, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine. 2015. ↩︎
Spangenberg EE, Lee RJ, Najafi AR, et al. Eliminating microglia in Alzheimer's disease models improves cognitive function. Glia. 2016. ↩︎
Stevens B, Allen NJ, Vazquez LE, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007. ↩︎